98%
921
2 minutes
20
Background: The Pooled Cohort Equations (PCEs) do not accurately estimate atherosclerotic cardiovascular disease (ASCVD) risk in certain populations. The 2018 AHA/ACC cholesterol guideline identified risk-enhancing factors as a supplement to PCEs-based risk assessment. However, the role of each risk-enhancing factor in ASCVD risk assessment has not been well quantified. Further, social determinants of health (SDOH) are not included in the PCEs nor considered as risk-enhancing factors in the US cholesterol guideline. We sought to evaluate ASCVD risk associated with each risk-enhancing factor and commonly collected SDOH including education, income, and employment status, and to assess if adding risk-enhancing factors and SDOH to the PCEs improve ASCVD risk prediction.
Methods: We included individuals aged 40 to 75 years, without ASCVD or diabetes at baseline, and with low-density lipoprotein cholesterol 70-189 mg/dL from two contemporary prospective cohort studies (MESA and REGARDS) and from Kaiser Permanente Southern California (KPSC). The primary endpoint was incident ASCVD defined as nonfatal myocardial infarction, fatal coronary heart disease, or fatal or nonfatal stroke over a 10-year period (median follow-up 10 years). We used Cox proportional hazards models to estimate associations between risk-enhancing factors and SDOH with ASCVD. We also assessed changes in model performance after adding risk-enhancing factors and SDOH to the PCEs.
Results: We included 13,863 adults (mean age 60.7 years) from the prospective cohorts and 307,931 adults (mean age 54.8 years) from KPSC. Risk-enhancing factors including hypercholesterolemia, hypertriglyceridemia, metabolic syndrome, and chronic kidney disease were associated with a higher ASCVD risk, independent of 10-year risk estimated by the PCEs. Low education, low income, and unemployment were also associated with higher ASCVD risk. While adding individual risk-enhancing factors or SDOH to the PCEs had limited impact on model performance, adding multiple risk-enhancing factors and SDOH simultaneously led to modest improvements in discrimination (C-index increased by up to 0.07), calibration (integrated Brier score reduced by up to 2.3%), and net reclassification improvement up to 41.4%.
Conclusions: These findings suggest including SDOH and risk-enhancing factors may improve ASCVD risk assessment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11508156 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0312756 | PLOS |
Transpl Immunol
September 2025
Department of Thoracic Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shannxi Province, China. Electronic address:
Post-transplant rejection is a serious problem for patients undergoing organ transplantation. It is currently believed that immune-related factors are the main causes of transplant rejection, but the roles of many immune cell phenotypes are still unclear. We utilized Mendelian randomization analysis to explore the association between 731 immune cell and the risk of transplant rejection.
View Article and Find Full Text PDFJACC Adv
August 2025
Department of Medicine, University of Texas Southwestern, Dallas, Texas, USA.
Background: Chronic kidney disease (CKD) is a risk-enhancing factor for cardiovascular disease (CVD) and is associated with higher lipoprotein(a) (Lp[a]) levels. While aspirin may reduce Lp(a)-related prothrombotic risk, the role of primary prevention aspirin for persons with CKD and elevated Lp(a) is unclear.
Objectives: The aim of the study was to assess the association of aspirin use with cardiovascular, renal, and bleeding outcomes stratified by Lp(a) level among individuals with CKD without clinical CVD.
Cardiol Rev
August 2025
Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY.
Elevated lipoprotein(a) [Lp(a)] has shown association with atherosclerotic cardiovascular disease and has been identified as a risk-enhancing factor contributing to the global morbidity and mortality associated with cardiovascular diseases. Lp(a) levels are not easily altered by classic lipid-lowering therapies such as statins. Recent developments in RNA-based therapeutics have led to the generation of drugs targeted to lowering Lp(a) levels by a variety of mechanisms.
View Article and Find Full Text PDFRespir Med
October 2025
Department of Cardiology, Navy 905 Hospital, Naval Medical University, Shanghai, 200052, China. Electronic address:
Background: In 2023, the American Heart Association presented a new condition, cardiovascular-kidney-metabolic (CKM) syndrome, recognized for its multistage and multisystem nature. Given that inflammatory condition can enhance the risk for CKM syndrome and asthma is a disease characterized by chronic airway inflammation, asthma could potentially increase the progression through CKM syndrome stages. The aim of the present study was to investigate the association between asthma and advanced CKM syndrome.
View Article and Find Full Text PDF